In today’s recent session, 0.62 million shares of the Trinity Biotech Plc ADR (NASDAQ:TRIB) have been traded, and its beta is 0.98. Most recently the company’s share price was $0.81, and it changed around -$0.07 or -7.99% from the last close, which brings the market valuation of the company to $9.21M. TRIB at last check was trading at a discount to its 52-week high of $3.55, offering almost -338.27% off that amount. The share price’s 52-week low was $0.85, which indicates that the recent value has fallen by an impressive -4.94% since then. We note from Trinity Biotech Plc ADR’s average daily trading volume that its 10-day average is 0.14 million shares, with the 3-month average coming to 183.33K.
Trinity Biotech Plc ADR (NASDAQ:TRIB) trade information
Instantly TRIB has been showing red trend so far today with a performance of -7.99% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.1200 on recent trading dayincreased the stock’s daily price by 27.68%. The company’s shares are currently down -62.25% year-to-date, but still down -25.72% over the last five days. On the other hand, Trinity Biotech Plc ADR (NASDAQ:TRIB) is -49.71% down in the 30-day period. We can see from the shorts that 94129.0 shares have been sold at a short interest cover period of 0.43 day(s).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Trinity Biotech Plc ADR (TRIB) estimates and forecasts
Trinity Biotech Plc ADR share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -72.08 percent over the past six months and at a 48.37% annual growth rate that is well above the industry average of 11.40%. The year-over-year growth rate is expected to be 9.44%, up from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of 16.5M in revenue for the current quarter. 1 analysts expect Trinity Biotech Plc ADR to make 16M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 8.81%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 9.90%. Trinity Biotech Plc ADR earnings are expected to increase by 63.87% in 2024, but the outlook is positive 15.00% per year for the next five years.
TRIB Dividends
Trinity Biotech Plc ADR’s next quarterly earnings report is expected to be released in January. The average dividend yield for the past five years averaged 1.19 per year.
